Patents by Inventor Robert Millman

Robert Millman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ARRDC1-Mediated Microvesicles (ARMMS) Degrading System and Uses Thereof
    Publication number: 20250034282
    Abstract: This invention relates generally to ARRDC1 fusion proteins, ARRDC1-mediated microvesicles (ARMMs) degrading systems, and their uses.
    Type: Application
    Filed: December 8, 2022
    Publication date: January 30, 2025
    Inventors: Robert Millman, Joseph Nabhan, Nicholas Buffinger
  • METHODS FOR TREATING HEMATOLOGIC CANCERS
    Publication number: 20240043541
    Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA4.
    Type: Application
    Filed: May 31, 2023
    Publication date: February 8, 2024
    Inventors: Bryon Duane Johnson, Robert Millman
  • Methods for treating hematologic cancers
    Patent number: 11708412
    Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA4.
    Type: Grant
    Filed: December 23, 2019
    Date of Patent: July 25, 2023
    Assignees: Novartis AG, The Medical College of Wisconsin, Inc.
    Inventors: Bryon Duane Johnson, Robert Millman
  • ARRDC1-MEDIATED MICROVESICLE-BASED DELIVERY TO THE NERVOUS SYSTEM
    Publication number: 20230227852
    Abstract: Methods, systems, compositions and strategies for the use of ARMM-mediated delivery of molecules (e.g., biological molecules, small molecules, proteins, and nucleic acids (e.g., DNA, RNA), DNA plasmids shRNA, mRNA) to cells of the nervous system (e.g., central nervous system and peripheral nervous system).
    Type: Application
    Filed: June 11, 2021
    Publication date: July 20, 2023
    Applicants: President and Fellows of Harvard College, The General Hospital Corporation, Vesigen, Inc.
    Inventors: Quan Lu, Stephen J. Haggarty, Robert Millman
  • METHODS FOR TREATING HEMATOLOGIC CANCERS
    Publication number: 20200377600
    Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA4.
    Type: Application
    Filed: December 23, 2019
    Publication date: December 3, 2020
    Inventors: Bryon Duane Johnson, Robert Millman
  • Methods for treating hematologic cancers
    Patent number: 10570204
    Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA-4. In one embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of TIM-3. In another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of LAG-3. In yet another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of CTLA-4.
    Type: Grant
    Filed: September 25, 2014
    Date of Patent: February 25, 2020
    Assignees: The Medical College of Wisconsin, Inc., Novartis AG
    Inventors: Bryon Duane Johnson, Robert Millman
  • METHODS FOR TREATING HEMATOLOGIC CANCERS
    Publication number: 20160222121
    Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA-4. In one embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of TIM-3. In another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of LAG-3. In yet another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of CTLA-4.
    Type: Application
    Filed: September 25, 2014
    Publication date: August 4, 2016
    Inventors: Bryon Duane Johnson, Robert Millman